Zhangjiang Hi-Tech Park Research Articles

Cryogenic System for Shanghai Synchrotron Radiation Facility

The Shanghai Synchrotron Radiation Facility (SSRF) is an intermediate energy light source built at Zhang-Jiang Hi-Tech Park in Shanghai, China. The RF power and voltage required for storing the electron beam are provided by means of three SC (superconducting) cryomodules, each containing one 500 MHz superconducting cavity. A cryogenic plant with cooling capacity of 650 W at 4,5 K (herein called SSRF-I cryoplant) supplied by Air Liquide advanced Technologies has been in operation since August of 2008 to provide cooling for the three superconducting cavities.In order to further improve the performance of SSRF, the following SC devices are to be applied for the SSRF upgrade (SSRF-II):1) 2 harmonic SRF (superconducting radio frequency) cavities with 1,5 GHz will run alternatively at 2 K (31 mbar).2) One superconducting wiggler is to be used for one of the new-built beam lines, ultra-hard multi-functional beam line. The SC wiggler will be cooled by cryocoolers at 4,2 K region.To support the operation of the new cavities, AL-aT (Air Liquide advanced Technologies) has designed, manufactured and started a new cryogenic system including a 2K system with equivalent cooling capacity of at least 650 W at 4,5 K and 60 W at 2K. The system is mainly constituted of a refrigerator HELIAL MF, an auxiliary 2 K cold box and of a 2 K warm pumping station.This cryogenic unit has been started successfully at the end of 2018 and has proven performances both at 4,5K and at 2K.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author 'Edward A. Kesicki' was misspelled as 'Ed Kesicki'. These errors have been corrected online.

Boehringer starts plant, expands China R&D

Boehringer Ingelheim has started up a $78 million biopharmaceutical plant at the Zhangjiang Hi-Tech Park in Shanghai. The facility, the company claims, is the only biopharmaceutical plant started up in China by a major international producer. Boehringer plans to use the plant to supply monoclonal antibodies and recombinant proteins to its customers in China. Separately, Boehringer announced that it will fund early drug discovery projects at Peking University. Several academic investigators will work closely with the German firm, Boehringer says.

Henkel opens Shanghai center

Henkel has inaugurated an adhesives-focused R&D center in Shanghai’s Zhangjiang Hi-Tech Park. Staffed with 100 scientists, the facility supports customers across Henkel’s businesses, with particular focus on automotive and construction applications. In comments to reporters, Christian Kirsten, Henkel’s head of adhesive technologies in Asia, noted that although the Chinese economy has slowed in recent months, demand for high-quality materials is gaining in strength.

Where does the source of external knowledge come from? A case of the Shanghai ICT chip industrial cluster in China

Purpose– The purpose of this paper is to: first, divide external knowledge into different levels and understand how these different levels of external knowledge create different knowledge networks. Second, explore the relation among different levels of external knowledge, different types of knowledge and their influences on innovation. Different types of knowledge may act as mediators between different levels of external knowledge and innovation performance are also discussed. Third, further explicate the possible reasons behind the phenomena observed in the first and second objectives.Design/methodology/approach– The quantitative and qualitative research methods were adopted in this study. In terms of the quantitative research method, data were collected from 157 information and communications technology (ICT) companies in Zhangjiang. There were 38 interviews carried out using the qualitative research method. Interviewees included 26 directors from the Zhangjiang ICT chip companies and 12 directors from China’s domestic mobile phone manufacturing sector.Findings– This study finds out that the source of external knowledge in the Zhangjiang Hi-Tech Park is mostly derived from cross-regional and cross-national connections. Through the connection with global companies, the firms in Zhangjiang acquire technical knowledge. Also, through the interaction with cross-regional companies, the firms in Zhangjiang absorb market knowledge. The results of this study indicate that the cross-regional connections are spurred by the increasing demand of the Chinese domestic market and the government’s support for cross-regional interactions. Cross-national connections are encouraged and led by the Chinese Government after China’s 3G communication standard is adopted.Research limitations/implications– This study is built upon a case study in Zhangjiang of China. The findings of this study may not be applicable to other countries or regions in China. Also, this study only focusses on the ICT industry in Zhangjiang. Knowledge from different industries is not included in this study. In addition, the formal and informal knowledge flow is neglected in this study as well.Practical implications– The findings of this study provide business executives and policymakers with a new way of thinking about the development of industrial clusters and local firms. Firms may be able to find new ways to raise innovation performance using different external knowledge.Originality/value– The major contribution of this study is an initial attempt to provide a comprehensive analysis of external knowledge of industrial clusters, different types of knowledge and their influences on innovation performance. Moreover, the mediating effects of different types of knowledge are also discussed.

Organic Carbonates from Natural Sources

ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTOrganic Carbonates from Natural SourcesHua Zhang, Hong-Bing Liu, and Jian-Min Yue*View Author Information State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, P. R. China*Tel.: +86 21 5080 6718. E-mail: [email protected]Cite this: Chem. Rev. 2014, 114, 1, 883–898Publication Date (Web):August 27, 2013Publication History Received1 November 2012Published online27 August 2013Published inissue 8 January 2014https://doi.org/10.1021/cr300430eCopyright © 2013 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views5798Altmetric-Citations121LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit Read OnlinePDF (3 MB) Get e-AlertsSUBJECTS:Bacteria,Chemical structure,Ethanol,Hydrocarbons,Inorganic carbon compounds Get e-Alerts

A Setback For Chinese Drug R&D

In Shanghai’s Zhangjiang Hi-Tech Park, shiny new R&D centers built by the world’s largest pharmaceutical companies tower near each other, even side by side in some cases. Large drug companies have downsized their Western R&D operations in recent years, but the opposite is happening in China, perhaps the world’s most promising drug market. Novartis, which already employs more than 400 scientists in Shanghai, is completing the construction of new facilities to accommodate more researchers. Merck & Co., with 200 researchers at work in Beijing, plans to increase its R&D headcount there to 600 in coming years and invest $1.5 billion in research facilities in the country. Among such companies, GlaxoSmithKline stands out as perhaps the most confident in trusting China-based researchers to conduct world-class, cutting-edge research. Since announcing in 2007 that it would set up an R&D base in Shanghai, GSK has built an organization of 400 scientists in the ...

HOMEGROWN R&D FLOWERS IN CHINA

IN A MEETING ROOM in a building resembling a residential home in Shanghai’s Zhangjiang Hi-Tech Park , Li Chen and John Choi describe the business plan of their new company. Called Hua Medicine, the firm will launch breakthrough drugs within four years, they predict. Hua will manufacture the compounds and sell them with its own sales force. It will also license its internally developed drugs to multinational companies. Yet right now, Hua is a modest operation that employs eight people. Hua doesn’t have an R&D lab yet, let alone a manufacturing facility. It operates in a loaned building formerly used by the administrators of the industrial park. Most entrepreneurs excel at talking convincingly about their new ventures. Over the past two years, optimistic executives and scientists have used these skills to launch research-based pharmaceutical companies in China that aim not only to discover and develop new drugs, but also to manufacture and distribute them. It ...

PHARMA STRATEGY Novartis makes major R&D and vaccines investments in China

Novartis has unveiled investments in China that are intended to help it capitalize on a population with increasing access to health care. The Swiss firm will sink $1 billion over the next five years into bolstering its R&D activities in China and will buy a majority stake in a Chinese vaccines company. Much of the R&D investment will go to the Novartis Institute for BioMedical Research in Shanghai (CNIBR). Focused on basic research into diseases that impact China, the institute will eventually house R&D in analytics and biomarkers, pharmacology, chemistry, proteomics and genomics, imaging, and protein production. The company expects to increase the number of associate-level scientists to roughly 1,000 from 160 today. To accommodate the added labs and manpower, CNIBR will move from Shanghai’s Zhangjiang Hi-Tech Park to a new campus in the city. Separately, Novartis signed a deal under which it will pay $125 million for an 85% stake in Zhenjiang Tianyuan Bio-Pharmaceutical, ...

LILLY DROPS AN ANCHOR IN SHANGHAI

LAST MONTH , a group of senior scientists from Eli Lilly & Co. started working out of an office in Shanghai’s Zhangjiang Hi-Tech Park. Rather than do research themselves, they are there to provide scientific leadership to the Chinese firms that Lilly has tasked with a steadily expanding range of R&D activities. “Large multinational drug companies conduct research in China either by building their own brick-and-mortar R&D centers or by building relationships with contract research organizations,” says Robert W. Armstrong, a Lilly vice president in charge of global external R&D. “We are in the second camp.” Non-U.S. pharmaceutical companies, including Novartis, AstraZeneca, Roche, and GlaxoSmithKline, have built or are in the process of building their own R&D centers in China. U.S. drug firms such as Lilly, Pfizer, and Merck & Co. have generally opted to take advantage of China’s scientists by collaborating with third parties there. Armstrong does not see the new coordination facility in Shanghai ...

Spontaneous vs. policy-driven: The origin and evolution of the biotechnology cluster

The biotechnology industry is at the heart of the fast-growing knowledge-based economy. One of the distinguishing characteristics of this industry is clustering. A cluster, like an organism, experiences origin, growth, and decline/reorientation. Our study constructs a framework to analyze biotechnology clusters with different origins, “spontaneous” and “policy-driven”, through their life cycles. We use the Bay Area in the United States and Shanghai Zhangjiang Hi-Tech Park in China as two cases to represent spontaneous and policy-driven biotechnology clusters. This study fills the gap in the literature by comparing these two types of biotechnology clusters in an evolutionary perspective. The key success factors of both biotechnology clusters are their own human and financial capital, but they differ in their underlying processes for creating and sharing these resources. The most fundamental differences arise from the impact of entrepreneurship, social capital and network patterns on the cluster's configuration.

MEDICILON STRIVES TO KEEP THE PACE

FIVE YEARS AGO, China was perceived by Western drug discovery researchers either as a supplier of competitively priced chemistry services or as a good place to conduct clinical trials on patients. Researchers did not go there to purchase biology services or get toxicology studies done. The idea of the three founders of Medicilon was to start offering these additional services and see what happened. Jintao Zhang, Chunlin Chen, and Cheney Mao launched their company in 2004, and it took off like a rocket. At its start, the firm employed just 20 people operating in 10,000 sq ft of lab space. By the end of 2008, it will have a staff of about 470 people and occupy 218,000 sq ft. In addition to its original facilities in Shanghai’s Zhangjiang Hi-Tech Park, Medicilon now operates a research campus close to the city’s international airport that consists of four multistory buildings. The company now is one of only ...

CHINA STRIDES TOWARD GLOBAL PHARMA ROLE

FOR A COUNTRY that fancies itself an emerging world power backed by thousands of years of history, China has a poor record in the pharmaceutical realm. It hasn't yet brought to market a single one of the major drugs that are sold around the world today. And China's drug industry is far better known for graft and unsafe practices than for its positive achievements. Yet, China's pharmaceutical industry is undergoing a major upgrade. Chinese who have spent decades living abroad are returning in large numbers to inject worldclass practices into the country's pharmaceutical business. This strong dose of talent is complemented by spirited government efforts to build up the R&D capabilities of universities and research institutes. I have confidence that, in the near future, we will have some drugs 100% made in China, says Ningni Yu, the executive in charge of promoting pharmaceutical business activities in Shanghai's Zhangjiang HiTech Park. Yu is well-known among executives ...